SLC
ABBV icon

Second Line Capital’s AbbVie ABBV Stock Holding History

Second Line Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
1,307
+3
+0.2% +$645 0.06% 112
2026
Q1 		$276K Sell
1,304
-180
-12% -$39.9K 0.05% 139
2025
Q4 		$339K Buy
1,484
+26
+2% +$5.92K 0.07% 102
2025
Q3 		$338K Sell
1,458
-320
-18% -$65.2K 0.07% 101
2025
Q2 		$330K Buy
1,778
+112
+7% +$20.8K 0.08% 97
2025
Q1 		$349K Buy
1,666
+504
+43% +$98K 0.09% 89
2024
Q4 		$206K Sell
1,162
-756
-39% -$139K 0.06% 122
2024
Q3 		$379K Buy
+1,918
New +$358K 0.1% 79

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Second Line Capital's ABBV Position: Q2 2026 in Review

Second Line Capital increased its AbbVie (ABBV) stake by 0.23% in Q2 2026, buying an estimated $645 and bringing the position to 1,307 shares worth $329K. The position accounts for 0.06% of the portfolio, ranked #112.

Second Line Capital first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. The position peaked at $379K in Q3 2024. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Second Line Capital held 1,307 shares of AbbVie worth $329K as of Q2 2026.
  • Second Line Capital bought 3 AbbVie shares in Q2 2026, an estimated $645.
  • AbbVie made up 0.06% of Second Line Capital's portfolio in Q2 2026, its #112 holding.
  • Second Line Capital first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • Second Line Capital's AbbVie position peaked at $379K in Q3 2024.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Second Line Capital's 13F filing for Q2 2026, filed 12 Aug 2026.